SweetValueLab
Write for us

Viking Therapeutics, Inc. — Financial Statements & Ratios

VKTX
NASDAQHealthcareBiotechnologyCIK 0001607678vikingtherapeutics.comAbout VKTX
Quant grade ?D
Last close · Oct 30, 202627.28+0.42 (+1.56%)

Key indicators

Revenue0TTM
Fiscal yearFY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025TTMFY2026EFY2027EFY2028E
Growth
0 0 0 0 0 0 0 0 0 7.2M 7.3M 217.2M
-$0.38 -$0.36+5.3%-$0.50−38.9%-$0.70−40.0%-$0.88−25.7%-$0.91−3.4%-$1.01−11.0%-$3.19−215.8%-$5.41−155.2%-$5.32 -$5.15 -$3.93
Profitability
-7.4% -9.3%−1.9 pt-16.2%−6.9 pt-27.2%−11.1 pt-47.4%−20.2 pt-24.7%+22.7 pt-12.5%+12.2 pt-56.3%−43.8 pt— · · ·
Cash
-18.8M -24.8M−32.0%-21.8M+12.0%-47.6M−118.5%-48.4M−1.7%-73.4M−51.6%-87.8M−19.6%-278.7M−217.4%-462.6M−106.0%· · ·
0 0 0 0 6.8M 0−100.0%0 0 — · · ·
Balance sheet
0.00x 0.00x+0.00x0.00x−0.00x0.00x−0.00x0.01x+0.01x0.00x−0.01x0.00x−0.00x0.00x−0.00x0.43x+0.43x· · ·
57.58M 71.96M+25.0%72.60M+0.9%77.20M+6.3%76.83M−0.5%94.35M+22.8%109.04M+15.6%112.67M+3.3%118.05M+5.1%· · ·

E = analyst consensus (revenue and EPS only). TTM = the twelve months to Sep 30, 2026: the last fiscal year, plus the quarters since, less the same quarters a year earlier. From the 10-K and the 10-Qs since; the shaded column is the latest period.